

# Catherine Schramm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9745088/publications.pdf>

Version: 2024-02-01

24  
papers

826  
citations

687363

13  
h-index

610901

24  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1690  
citing authors

#	ARTICLE	IF	CITATIONS
1	MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects. <i>Human Genetics</i> , 2022, 141, 65-80.	3.8	14
2	Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes. <i>Genome Medicine</i> , 2022, 14, .	8.2	7
3	Effect Sizes of Deletions and Duplications on Autism Risk Across the Genome. <i>American Journal of Psychiatry</i> , 2021, 178, 87-98.	7.2	50
4	Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers. <i>Acta Neuropathologica</i> , 2021, 142, 259-278.	7.7	8
5	Effects of eight neuropsychiatric copy number variants on human brain structure. <i>Translational Psychiatry</i> , 2021, 11, 399.	4.8	18
6	Genome-wide analysis of gene dosage in 24,092 individuals estimates that 10,000 genes modulate cognitive ability. <i>Molecular Psychiatry</i> , 2021, 26, 2663-2676.	7.9	33
7	Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 196.	5.2	17
8	Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia. <i>Nature Communications</i> , 2020, 11, 5272.	12.8	35
9	Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase <sc>II</sc> Trial. <i>Movement Disorders</i> , 2020, 35, 1323-1335.	3.9	16
10	Dysregulation of peripheral expression of the YWHA genes during conversion to psychosis. <i>Scientific Reports</i> , 2020, 10, 9863.	3.3	12
11	Estimating the effects of copy number variants on intelligence using hierarchical Bayesian models. <i>Genetic Epidemiology</i> , 2020, 44, 825-840.	1.3	1
12	Combining Whole-Genome Sequencing and Multimodel Phenotyping To Identify Genetic Predictors of <i>Salmonella</i> Virulence. <i>MSphere</i> , 2020, 5, .	2.9	9
13	KSPM: A Package For Kernel Semi-Parametric Models. <i>R Journal</i> , 2020, 12, 189.	1.8	2
14	How to analyze and interpret recurrent events data in the presence of a terminal event: An application on readmission after colorectal cancer surgery. <i>Statistics in Medicine</i> , 2019, 38, 3476-3502.	1.6	11
15	Clustering of longitudinal data by using an extended baseline: A new method for treatment efficacy clustering in longitudinal data. <i>Statistical Methods in Medical Research</i> , 2018, 27, 97-113.	1.5	2
16	Measuring and Estimating the Effect Sizes of Copy Number Variants on General Intelligence in Community-Based Samples. <i>JAMA Psychiatry</i> , 2018, 75, 447.	11.0	77
17	The role of the striatum in linguistic selection: Evidence from Huntington's disease and computational modeling. <i>Cortex</i> , 2018, 109, 189-204.	2.4	34
18	Interventions to reduce nurses' medication administration errors in inpatient settings: A systematic review and meta-analysis. <i>International Journal of Nursing Studies</i> , 2016, 53, 342-350.	5.6	75

#	ARTICLE	IF	CITATIONS
19	COMT Val158Met Polymorphism Modulates Huntington's Disease Progression. PLoS ONE, 2016, 11, e0161106.	2.5	17
20	Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks. PLoS ONE, 2015, 10, e0143440.	2.5	34
21	Management of Large-Vessel Vasculitis With FDG-PET. Medicine (United States), 2015, 94, e622.	1.0	227
22	How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease. PLoS ONE, 2015, 10, e0145842.	2.5	10
23	Treatment for Stable Coronary Artery Disease: A Network Meta-Analysis of Cost-Effectiveness Studies. PLoS ONE, 2014, 9, e98371.	2.5	23
24	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer. Cancer Research, 2014, 74, 5008-5018.	0.9	83